Wall Street analysts predict that Acorda Therapeutics Inc (NASDAQ:ACOR) will report ($0.97) earnings per share for the current quarter, Zacks reports. Four analysts have provided estimates for Acorda Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.85) and the lowest estimate coming in at ($1.04). Acorda Therapeutics reported earnings per share of $0.14 in the same quarter last year, which would suggest a negative year over year growth rate of 792.9%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, May 1st.
On average, analysts expect that Acorda Therapeutics will report full year earnings of ($3.84) per share for the current year, with EPS estimates ranging from ($4.20) to ($3.30). For the next financial year, analysts forecast that the business will report earnings of ($3.32) per share, with EPS estimates ranging from ($4.31) to ($2.70). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Thursday, February 14th. The biopharmaceutical company reported $0.45 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.19) by $1.64. Acorda Therapeutics had a return on equity of 12.98% and a net margin of 7.14%. The company had revenue of $69.20 million during the quarter, compared to analysts’ expectations of $48.12 million. During the same quarter in the previous year, the business earned $0.61 earnings per share. The firm’s revenue for the quarter was down 63.3% on a year-over-year basis.
In other news, major shareholder Scopia Capital Management Lp sold 100,000 shares of the business’s stock in a transaction that occurred on Thursday, January 17th. The stock was sold at an average price of $16.86, for a total value of $1,686,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 216,605 shares of company stock worth $3,550,802. Corporate insiders own 7.80% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. grew its holdings in Acorda Therapeutics by 13.9% during the fourth quarter. American Century Companies Inc. now owns 163,432 shares of the biopharmaceutical company’s stock worth $2,546,000 after acquiring an additional 19,909 shares during the period. Norges Bank acquired a new position in Acorda Therapeutics during the fourth quarter worth $14,675,000. Public Employees Retirement System of Ohio grew its holdings in Acorda Therapeutics by 139.5% during the fourth quarter. Public Employees Retirement System of Ohio now owns 21,915 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 12,764 shares during the period. Municipal Employees Retirement System of Michigan acquired a new position in Acorda Therapeutics during the fourth quarter worth $175,000. Finally, Metropolitan Life Insurance Co. NY grew its holdings in Acorda Therapeutics by 369.0% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 14,539 shares of the biopharmaceutical company’s stock worth $227,000 after acquiring an additional 11,439 shares during the period.
NASDAQ ACOR traded up $0.01 on Thursday, reaching $11.93. The stock had a trading volume of 801,696 shares, compared to its average volume of 867,714. The company has a current ratio of 3.77, a quick ratio of 3.56 and a debt-to-equity ratio of 0.56. Acorda Therapeutics has a 12-month low of $11.81 and a 12-month high of $36.35. The stock has a market cap of $567.75 million, a P/E ratio of 6.55 and a beta of 1.47.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
Recommended Story: What is dollar cost averaging (DCA)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.